Colla Laboratory
Simona Colla, Ph.D.
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Colla Laboratory
Areas of Research
- Leukemia Research
- Myelodysplastic Syndrome Research
- Cancer Biology Research
- Molecular Biology Research
- Single-Cell Genomics Research
Welcome to the Colla Lab at MD Anderson Cancer Center. We are a basic and translational lab in the Leukemia department. Our researchers use multidisciplinary approaches and model systems to gain a deep understanding of the cellular and molecular mechanisms that drive hematologic malignancies (blood cancers).
Our goal is to improve the clinical outcome of patients with Myelodysplastic Syndromes (MDS) and Multiple Myeloma (MM) by making scientific advances that allow us to better understand the molecular mechanisms that drive these hematological malignancies.
Specific Aims
- Identify biological mechanisms of therapeutic resistance and develop successful strategies to overcome this resistance
- Leverage insights from basic studies to identify targetable networks
- In vivo analysis to test drug efficacy to develop novel therapies
To develop novel treatment strategies, our research employs an integrative toolbox that includes genomic, molecular, proteomic and cellular analyses, as well as PDX and GEM mouse models.
Recent Publications
-
2022 - Blood Cancer Discovery
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
Vera Adema and Simona Colla
-
Nature Medicine
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Irene Ganan-Gomez and Simona Colla
-
2021 - Nature Communications
Hematopoiesis under telomere attrition at the single-cell resolution
Nattakan Thongon and Simona Colla
Funding
Funding support for the Colla Laboratory includes the Leukemia and Lymphoma Society, MD Anderson Cancer Center Moon Shots Program®, National Institutes of Health/National Cancer Institute and Evans MDS Foundation.